News | Robotic Systems | December 28, 2017

Corindus and Houston Methodist DeBakey Heart & Vascular Center Launch Robotic Training Site

Facility with two CorPath GRX Systems will provide virtual and hands-on introduction to robotic-assisted cath lab procedures

Corindus and Houston Methodist DeBakey Heart & Vascular Center Launch Robotic Training Site

December 28, 2017 — Corindus Vascular Robotics Inc. announced recently that Houston Methodist DeBakey Heart & Vascular Center has launched the first vascular robotic program in the Houston area with the installation of two Corindus CorPath GRX Systems. In addition and as part of the program launch, Corindus will partner with Houston Methodist to develop a Global Center of Excellence that will seek to advance clinical research on robotics and to train interventional cardiologists on robotic-assisted percutaneous coronary interventions (PCI).

The Houston Methodist Institute for Technology, Innovation & Education (MITIE), a virtual hospital and hands-on clinical training facility, will be a robotic-assisted PCI training center. Physicians attending courses at Houston Methodist will participate in didactic education, live case observation with a trained robotic interventionalist, and a workshop for a hands-on introduction to robotic-assisted PCI.

Alan Lumsden, M.D., chief of the Department of Cardiovascular Surgery at Houston Methodist, stated, "We pride ourselves on leading the way in embracing innovative technologies that improve patient care. With adoption of robotics in the cath lab on the rise, comprehensive training programs and innovative product developments are key factors for success."

For more information: www.corindus.com

Related Content

Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System

Corindus Announces First Patient Enrolled in PRECISION GRX Registry

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...